VIVS
VivoSim Labs, INC.
$1.19
-0.83%
$3.1M
No data for this timeframe.
Vol
Market Cap$3.1M
Cap SizeNano Cap
Inst. Holders5 funds
Inst. Value$62.3K
Inst. Activity0 buys / 1 sells
SEC Reports2
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001497253·Prev Close $1.20
Recent Activity
Apr 3, 2026
SEC
VivoSim Labs raised approximately $2.5 million in the initial tranche of a $4 million best-efforts public offering, issu
8-K — Impact 5/10
Apr 1, 2026
SEC
VivoSim Labs' IPO has become effective, allowing the company to begin selling up to $4 million in common stock, pre-fund
EFFECT — Impact 5/10
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
11,830 shares ($21.4K)
Inst.
TWO SIGMA INVESTMENTS, LP — NEW
23,192 shares ($67.7K)
Jun 3, 2026
earnings_calendar
VIVS Q4 2025 Earnings Before Market Open — 2026-06-03
Apr 1, 2026
Press
VivoSim Labs announced the pricing of a $4 million best-efforts public offering, with $3 million expected at an initial
Impact 6/10
Analyst Ratings
0Strong Buy
0Buy
4Hold
1Sell
2Strong Sell
Latest Reports
NEUTRAL
8-K
5/10
VivoSim Labs raised approximately $2.5 million in the initial tranche of a $4 million best-efforts public offering, issu
Apr 3, 2026
BEARISH
Press
6/10
VivoSim Labs announced the pricing of a $4 million best-efforts public offering, with $3 million expected at an initial
Apr 1, 2026
NEUTRAL
EFFECT
5/10
VivoSim Labs' IPO has become effective, allowing the company to begin selling up to $4 million in common stock, pre-fund
Apr 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $40.5K | NEW |
| TWO SIGMA INVESTMENTS, LP | $21.4K | TRIM |
| WELLS FARGO & COMPANY/MN | $211.00 | TRIM |
| MORGAN STANLEY | $123.00 | NEAR_EXIT |
| BANK OF AMERICA CORP | $53.00 | ADD |
5 institutional holders with $62.3K total value (34,418 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, WELLS. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 22,374 | $40.5K | 65.0% | NEW |
| 2 | TWO SIGMA INVESTMENTS, LP | 11,830 | $21.4K | 34.4% | TRIM -49.0% |
| 3 | WELLS FARGO & COMPANY/MN | 117 | $211.00 | 0.3% | TRIM -25.6% |
| 4 | MORGAN STANLEY | 68 | $123.00 | 0.2% | NEAR_EXIT -98.6% |
| 5 | BANK OF AMERICA CORP /DE/ | 29 | $53.00 | 0.1% | ADD +43.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | TRIM | 23,192 | 11,830 | -49.0% | $21.4K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 23,192 | — | $67.7K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 160 | 119 | -25.6% | $347.00 | 2025-Q3 |
| FMR LLC | DOUBLED | 10 | 25 | +150.0% | $73.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 53 | 14,104 | +26511.3% | $20.7K | 2025-Q2 |
| MORGAN STANLEY | NEAR_EXIT | 4,990 | 72 | -98.6% | $106.00 | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 23 | 33 | +43.5% | $48.00 | 2025-Q2 |
| VANGUARD GROUP INC | NEW | — | 22,374 | — | $50.1K | 2025-Q1 |
| MORGAN STANLEY | NEW | — | 4,990 | — | $11.2K | 2025-Q1 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.
Historical analyst distribution: 0% buy across 7 analysts — 0 strong buy, 0 buy, 4 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2025-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Dec 1, 2021 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Nov 1, 2021 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Oct 1, 2021 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Sep 1, 2021 | 0 | 0 | 4 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
earnings_calendar
VIVS Q4 2025 Earnings Before Market Open — 2026-06-03
Apr 28, 2026
other
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results <pre>VivoSim’s NAMkind™ Intestinal Model combined w
Apr 1, 2026
offering
VivoSim Announces Pricing of up to a $4 Million Public Offering
<p align="justify">SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS), (the “Company” or “VivoSim”), a provider of next
Mar 24, 2026
other
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry to
Mar 3, 2026
other
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth alon
Feb 3, 2026
short_interest
FTD: VIVS — 403,871 shares ($1.0M) failed to deliver
Settlement: 20260203, Price: $2.43, FTD Value: $981,406.53, VIVOSIM LABS, INC. COMMON STOC
Feb 2, 2026
short_interest
FTD: VIVS — 755,728 shares ($2.2M) failed to deliver
Settlement: 20260202, Price: $2.92, FTD Value: $2,206,725.76, VIVOSIM LABS, INC. COMMON STOC